Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications

(2012) V. Ashutosh Rao   ANTIOXIDANTS & REDOX SIGNALING

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export

(2012) Y. Ichikawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics

(2011) Xavier Marechal et al.   CLINICAL SCIENCE

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group

(2009) W L Salzer et al.   LEUKEMIA

Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways

(2008) Leo I. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

(2008) O. Popelova et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

(2008) Elke Martin et al.   TOXICOLOGY